Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Clinical variables</td><td class="align_center">Clinical values (<i>N</i> = 185)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Sex (male/female)</td><td class="align_center">98/80</td></tr><tr><td class="align_left">Age (mean ± std)</td><td class="align_center">64.70 ± 11.13</td></tr><tr><td class="align_left">Race (Asian/black/white/NA)</td><td class="align_center">11/7/155/14</td></tr><tr><td class="align_left">Pathologica stage (I/II/III/IV/V/NA)</td><td class="align_center">19/21/147/4/5/3</td></tr><tr><td class="align_left">Pathologic_T stage (T1/T2/T3/T4/NA)</td><td class="align_center">7/21/144/4/2</td></tr><tr><td class="align_left">Pathologic_N stage (N0/N1/NA)</td><td class="align_center">48/125/5</td></tr><tr><td class="align_left">Pathologic_N stage (M0/M1/NA)</td><td class="align_center">83/5/90</td></tr><tr><td class="align_left">Grade (G1/G2/G3/G4/G<i>x</i>/NA)</td><td class="align_center">29/94/50/2/3</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

BioMed Research International

tab1

Table 1

Table 1: Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma 